Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 1/2 2Phase 2 1

Status

Completed 4Terminated 2Active not recruiting 1

Sponsor Class

OTHER 5INDUSTRY 1INDIV 1

Study Type

Interventional 7

Sponsor

Cancer Type

Dermatologic 7Other hematologic neoplasm 5Thoracic 3Gynecologic 3Plasma cell 2Myeloid 2Genitourinary 2Gastrointestinal 2Other solid neoplasm 1Lymphoid 1CNS 1Breast 1

Conditions

Melanoma 7Neoplasms 2Skin Neoplasms 1Carcinogenesis 1

Interventions

pembrolizumab 339Nivolumab 305Ipilimumab 274Cyclophosphamide 195aldesleukin 148Interleukin-2 110fludarabine phosphate 107trametinib 85Temozolomide 83fludarabine 81Dacarbazine 81dabrafenib 77Radiotherapy 75Biopsy 75Vemurafenib 71Imiquimod 53Bevacizumab 51sargramostim 50Magnetic Resonance Spectroscopy 50Specimen Handling 49Radiosurgery 49Peripheral Blood Stem Cell Transplantation 49Paclitaxel 49Aminolevulinic Acid 49binimetinib 48Carboplatin 48Blood Specimen Collection 47cemiplimab 46Cisplatin 453-ingenyl angelate 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Monatide (IMS 3015) × Dermatologic × Clear all
NCT03929029 2026-01-05

Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma

Dana-Farber Cancer Institute

Phase 1 Active not recruiting
11 enrolled 11 charts
Dermatologic

Melanoma

NCT01810016 2022-10-12

NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma

Ludwig Institute for Cancer Research

Phase 1 Terminated
8 enrolled 16 charts
Dermatologic

Melanoma, Neoplasms

NCT00112242 2020-06-18

Immunotherapy of Stage III/IV Melanoma Patients

Centre Hospitalier Universitaire Vaudois

Phase 1 Completed
39 enrolled 18 charts
Dermatologic

Melanoma

NCT01308294 2020-06-11

LAG-3/IMP321

Centre Hospitalier Universitaire Vaudois

Phase 1/2 Terminated
16 enrolled 12 charts
Dermatologic

Melanoma

NCT01079741 2018-02-13

Safety Study of Adjuvant Vaccine to Treat Melanoma Patients

Icahn School of Medicine at Mount Sinai

Phase 1/2 Completed
34 enrolled 10 charts
Dermatologic

Melanoma, Neoplasms, Skin Neoplasms, Carcinogenesis

NCT00124124 2015-02-13

Comparison of Dendritic Cells Versus Montanide as Adjuvants in a Melanoma Vaccine

Bhardwaj, Nina, M.D.

Phase 1 Completed
50 enrolled
Dermatologic

Melanoma

NCT00651703 2010-11-15

Safety and Immunogenicity of CYT004-MelQbG10 Vaccine With and Without Adjuvant in Advanced Stage Melanoma Patients

Cytos Biotechnology AG

Phase 2 Completed
21 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡